ALNY – Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.ALNY
$159.85Name : Alnylam Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $21,409,923,072.00
EPSttm : 19.8
Alnylam Pharmaceuticals, Inc.
$159.85
5.41%$8.21
ALNY — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
4.09
Margin Of Safety %
78
Put/Call OI Ratio
0.58
EPS Next Q Diff
-13.1
EPS Last/This Y
17.6
EPS This/Next Y
-11.85
Price
159.8
Target Price
298
Analyst Recom
1.71
Performance Q
-29.62
Upside
61.0%
Beta
0.45
Ticker: ALNY
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-10-13 | ALNY | 224.58 | 0.65 | 0.59 | 39741 |
| 2026-10-14 | ALNY | 224.42 | 0.65 | 0.74 | 39766 |
| 2026-10-15 | ALNY | 234.03 | 0.64 | 0.60 | 39764 |
| 2026-10-16 | ALNY | 231.85 | 0.65 | 0.11 | 40962 |
| 2026-10-19 | ALNY | 233.45 | 0.64 | 1.04 | 36254 |
| 2026-10-20 | ALNY | 230.78 | 0.63 | 8.75 | 37503 |
| 2026-10-21 | ALNY | 225.04 | 0.70 | 0.72 | 39186 |
| 2026-10-22 | ALNY | 227.35 | 0.69 | 1.87 | 39613 |
| 2026-10-23 | ALNY | 223.96 | 0.67 | 0.25 | 39436 |
| 2026-10-26 | ALNY | 227.59 | 0.67 | 1.88 | 39501 |
| 2026-10-27 | ALNY | 226.69 | 0.68 | 1.27 | 39864 |
| 2026-10-28 | ALNY | 232.94 | 0.69 | 0.57 | 40438 |
| 2026-10-29 | ALNY | 173.93 | 0.68 | 0.19 | 41840 |
| 2026-10-30 | ALNY | 164.86 | 0.54 | 0.22 | 45851 |
| 2026-11-02 | ALNY | 157.99 | 0.54 | 0.59 | 46789 |
| 2026-11-03 | ALNY | 159.86 | 0.52 | 0.87 | 47740 |
| 2026-11-04 | ALNY | 160.99 | 0.53 | 2.48 | 48947 |
| 2026-11-05 | ALNY | 156.47 | 0.56 | 3.45 | 50770 |
| 2026-11-06 | ALNY | 155.88 | 0.63 | 0.48 | 53564 |
| 2026-11-09 | ALNY | 156.54 | 0.62 | 1.06 | 53723 |
| 2026-11-10 | ALNY | 151.54 | 0.58 | 0.24 | 53888 |
| 2026-11-11 | ALNY | 159.77 | 0.58 | 1.40 | 55771 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-10-13 | ALNY | 223.82 | -21.2 | 936.7 | 8.83 |
| 2026-10-14 | ALNY | 224.50 | -21.2 | 975.2 | 8.83 |
| 2026-10-15 | ALNY | 233.94 | -20.8 | 1069.9 | 8.91 |
| 2026-10-16 | ALNY | 231.96 | -20.8 | 948.5 | 8.91 |
| 2026-10-19 | ALNY | 233.39 | -22.0 | 983.4 | 8.94 |
| 2026-10-20 | ALNY | 233.39 | -22.0 | 983.4 | 8.94 |
| 2026-10-21 | ALNY | 230.80 | -22.0 | 944.4 | 8.94 |
| 2026-10-22 | ALNY | 227.35 | -22.0 | 990.8 | 8.92 |
| 2026-10-23 | ALNY | 224.01 | -22.0 | 935.4 | 8.92 |
| 2026-10-26 | ALNY | 227.54 | -22.4 | 1003.6 | 8.86 |
| 2026-10-27 | ALNY | 226.72 | -22.4 | 959.0 | 8.83 |
| 2026-10-28 | ALNY | 232.31 | -22.4 | 1022.9 | 8.83 |
| 2026-10-29 | ALNY | 173.88 | -22.4 | 404.3 | 8.83 |
| 2026-10-30 | ALNY | 164.90 | -22.4 | 848.4 | 8.83 |
| 2026-11-02 | ALNY | 157.94 | -22.4 | 910.2 | 8.83 |
| 2026-11-03 | ALNY | 159.85 | 90.7 | 937.3 | 22.67 |
| 2026-11-04 | ALNY | 161.01 | 90.7 | 1026.7 | 22.67 |
| 2026-11-05 | ALNY | 156.49 | 90.7 | 807.0 | 22.61 |
| 2026-11-06 | ALNY | 155.95 | 86.7 | 859.3 | 22.61 |
| 2026-11-09 | ALNY | 156.47 | 86.7 | 876.8 | 22.61 |
| 2026-11-10 | ALNY | 151.55 | 86.7 | 798.3 | 22.61 |
| 2026-11-11 | ALNY | 159.80 | 93.7 | 987.9 | 22.68 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-10-13 | ALNY | -1.29 | -0.55 | 5.78 |
| 2026-10-14 | ALNY | -1.29 | -0.55 | 5.78 |
| 2026-10-15 | ALNY | -1.29 | -0.55 | 5.78 |
| 2026-10-16 | ALNY | -1.29 | -0.55 | 5.78 |
| 2026-10-19 | ALNY | -1.29 | -0.99 | 5.78 |
| 2026-10-20 | ALNY | -1.29 | -0.99 | 5.78 |
| 2026-10-21 | ALNY | -1.29 | -0.99 | 5.78 |
| 2026-10-22 | ALNY | -1.29 | -0.99 | 5.78 |
| 2026-10-23 | ALNY | -1.29 | -0.99 | 5.78 |
| 2026-10-26 | ALNY | -1.29 | -1.11 | 5.78 |
| 2026-10-27 | ALNY | -1.29 | -1.11 | 4.92 |
| 2026-10-28 | ALNY | -1.29 | -1.11 | 4.92 |
| 2026-10-29 | ALNY | -1.29 | -1.11 | 4.92 |
| 2026-10-30 | ALNY | -1.29 | -1.11 | 4.92 |
| 2026-11-02 | ALNY | -1.29 | -1.31 | 4.92 |
| 2026-11-03 | ALNY | -1.29 | -1.31 | 4.92 |
| 2026-11-05 | ALNY | -1.29 | -1.31 | 4.92 |
| 2026-11-06 | ALNY | -1.29 | -1.31 | 4.92 |
| 2026-11-09 | ALNY | -1.29 | 0.76 | 4.92 |
| 2026-11-10 | ALNY | -1.29 | 0.76 | 4.92 |
| 2026-11-11 | ALNY | -1.29 | 0.76 | 4.09 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
15.72
Avg. EPS Est. Current Quarter
2.42
Avg. EPS Est. Next Quarter
2.62
Insider Transactions
-1.29
Institutional Transactions
0.76
Beta
0.45
Average Sales Estimate Current Quarter
1521
Average Sales Estimate Next Quarter
1525
Fair Value
283.72
Quality Score
97
Growth Score
77
Sentiment Score
16
Actual DrawDown %
67.8
Max Drawdown 5-Year %
-69.1
Target Price
298
P/E
8.07
Forward P/E
17.83
PEG
0.26
P/S
4.27
P/B
5.94
P/Free Cash Flow
28.47
EPS
19.8
Average EPS Est. Cur. Y
22.68
EPS Next Y. (Est.)
10.83
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
54.34
Relative Volume
1.71
Return on Equity vs Sector %
47.1
Return on Equity vs Industry %
66.7
EPS 1 7Days Diff
0.1
EPS 1 30Days Diff
13.85
EBIT Estimation
987.9
◆
ALNY
Healthcare
$159.85
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
28.6
Range 1M
9.2%
Sup Dist
7.7%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
690.5%
EPS NY
-51.3%
52W%
2.5%
Long-Term Value
Quality companies, undervalued
WATCH
🟢 BUY
+34.6% upside
Upside
+34.6%
Quality
97
MoS
78%
ALNY — P/E HistoricalBiotechnology
Alnylam Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 2500
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
ALNY
Latest News
—
Caricamento notizie per ALNY…
stock quote shares ALNY – Alnylam Pharmaceuticals, Inc. Stock Price stock today
news today ALNY – Alnylam Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ALNY – Alnylam Pharmaceuticals, Inc. yahoo finance google finance
stock history ALNY – Alnylam Pharmaceuticals, Inc. invest stock market
stock prices ALNY premarket after hours
ticker ALNY fair value insiders trading